Étiquette : prescriptions

Three New Studies on Cannabis and PTSD, Nate Seltenrich, 2022

THREE NEW STUDIES ON CANNABIS AND PTSD Growing numbers of trauma sufferers are medicating with cannabis and finding it helpful. NATE SELTENRICH 31 décembre 2022 In recent years, psilocybin and MDMA have been explored as potential treatments for post-traumatic stress disorder, but somewhat more quietly so has cannabis. In fact, according to a few quick searches of PubMed, cannabis has a longer and richer association with PTSD in the scientific literature than any psychedelic. Though you wouldn’t know that by reading the headlines. Setting aside for a minute how effective psychedelics may or may not be as breakthrough treatments for PTSD, there’s no doubt that [...]

Lire la suite

Attitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians, Neta HaGani et al., 2021

Attitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians Neta HaGani, Sharon Sznitman, Michael Dor, Gil Bar-Sela, Dana Oren, Lilia Margolis-Dorfman, Itay Goor-Aryeh & Manfred S. Green Journal of Psychoactive Drugs, 2021, 1-10. Doi : 10.1080/02791072.2021.2009598   ABSTRACT Gaps between physician and patient perceptions may lead to misunderstandings and mismanage of treatment. There are sparse data about the differences in opinions toward medical cannabis (MC) between patients and health professionals. The aim of this study was to examine the attitudes toward MC, its perceived efficacy, side effects and risk of dependency, among patients, [...]

Lire la suite

Opioid and healthcare service use in medical cannabis patients with chronic pain : a prospective study, Sharon Sznitman et al., 2021

Opioid and healthcare service use in medical cannabis patients with chronic pain: a prospective study Sharon Sznitman, Carolyn Mabouk, Zahi Said and Simon Vulfsons British Medical Journal, 2021. doi : 10.1136/bmjspcare-2020-002661 Abstract Background Various jurisdictions have legalised medical cannabis (MC) for use in chronic pain treatment. The objective of this study was to determine if the use of MC is related to a reduction in the use of prescription opioids and other prescription medications and healthcare services. Methods : A retrospective cohort study was conducted using the medical files of 68 Israeli patients with chronic pain using MC. Number of prescription medications filled and healthcare services [...]

Lire la suite

Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand, Graham Gulbransen et al, 2020

Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand Graham Gulbransen, MBChB, FAChAM, FRNZCGP1*, William Xu2, Bruce Arroll, MBChB, PhD, FRNZCG BJGP Open, 2020, 1-8 DOI : 10.3399/bjgpopen20X101010   Abstract Background : Cannabidiol (CBD) is the non- euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear. Aim : To review the changes in self- reported quality of life measurements, drug tolerability, and dose- dependent relationships in patients prescribed CBD oil for various conditions at a single institution. Design & setting : An [...]

Lire la suite

Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis, Chad Purcell,

Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis Chad Purcell, Andrew Davis, Nico Moolman, and S. Mark Taylor Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, Doi : 10.1089/can.2018.0020   Abstract Background : Benzodiazepines are a class of medication with sedative properties, commonly used for anxiety and other neurological conditions. These medications are associated with several well-known adverse effects. This observational study aims to investigate the reduction of benzodiazepine use in patients using prescribed medical cannabis. Methods : A retrospective analysis was performed on a cohort of 146 medical cannabis patients (average age 47 years, 61% female, 54% reporting prior use of cannabis) who reported [...]

Lire la suite

Cannabis « médical » contre cannabis « récréatif » : une vision trop simpliste, Nicolas Authier, The Conversation, 22 janvier 2020

Cannabis « médical » contre cannabis « récréatif » : une vision trop simpliste Nicolas Authier, The Conversation, 22 janvier 2020 https://theconversation.com/cannabis-medical-contre-cannabis-recreatif-une-vision-trop-simpliste-129090   Ponctuel ou régulier, seul ou en groupe, pour soulager une souffrance ou chercher une convivialité… L’usage du cannabis diffère selon que sa finalité est médicale ou non médicale. En France, l’usage médical du cannabis, sous forme de médicament, est autorisé depuis 2013, sous forme de spécialités pharmaceutiques. Cet usage médical est généralement opposé à l’usage dit « récréatif ». Cependant, si cette description simplifiée facilite les questions de réglementation, elle ne permet pas, du point de vue de la santé publique, de proposer [...]

Lire la suite

Il y a urgence à prescrire du cannabis dans les Ehpad, Jean-Yves Nau et William Lowenstein, Slate.fr, 16 avril 2020

Il y a urgence à prescrire du cannabis dans les Ehpad Jean-Yves Nau et William Lowenstein — 16 avril 2020 à 10h58 http://www.slate.fr/story/189561/confinement-urgence-prescrire-cannabis-personnes-agees-ehpad Surconfiner les personnes âgées conduit à une consommation désastreuse de benzodiazépines et d'antalgiques opiacés. C'est oublier les vertus alternatives du cannabis médical. La maniabilité de l'administration du cannabis thérapeutique, notamment sous forme de tisanes, est fort intéressante. | Kimzy Nanney via Unsplash Combien, avant l'épidémie, se souciaient des Ehpad, de leurs résident·es, de leurs soignant·es? Combien étions-nous à connaître la signification de cet étrange acronyme, Établissement d'hébergement pour personnes âgées dépendantes? La progression fulgurante du SARS-CoV-2, quelques reportages, de douloureux témoignages, [...]

Lire la suite

Benefits and adverse effects of cannabis use among adults with persistent pain, Teresa Bigand et al., 2019

Benefits and adverse effects of cannabis use among adults with persistent pain Teresa Bigand, Cristina Lee Anderson, Mary Lee Roberts, Michele Rose Shaw, Marian Wilson Nursing Outlook, 2 0 1 9 , 67, 2 2 3 -2 3 1 doi : 10.1016/j.outlook.2018.12.014.   A B S T R A C T Background : Increasingly, states are legalizing cannabis for recreational use. Improved accessibility may allow adults with pain to use cannabis more liberally. Greater understanding is needed about how adults with pain perceive the effects of cannabis, particularly those who also use opioid analgesics. Purpose : To examine the perceived effects of cannabis among adults who have [...]

Lire la suite

Bibliographie : Cannabidiol (CBD), Docteur Christian SUEUR, GRECC, avril 2020.

Bibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020.     voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives    

Lire la suite